Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy

Oncogene

Volumn 34, Issue 46, 2015, Pages 5739-5748

  Lau, E ^a   Sedy, J ^a   Sander, C ^b   Shaw, M A ^c   Feng, Y ^a   Scortegagna, M ^a   Claps, G ^a   Robinson, S ^d   Cheng, P ^e   Srivas, R ^f   Soonthornvacharin, S ^a   Ideker, T ^g   Bosenberg, M ^h   Gonzalez, R ^d   Robinson, W ^d   Chanda, S K ^a   Ware, C ^a   Dummer, R ^e   Hoon, D ^c   Kirkwood, J M ^b   Ronai, Z A ^a   more..

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^h YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ALPHA2A INTERFERON; BETA1 INTERFERON; BEVACIZUMAB; CISPLATIN; DACARBAZINE; ETOPOSIDE; INTERFERON REGULATORY FACTOR 9; INTERLEUKIN 2; IPILIMUMAB; MESSENGER RNA; PACLITAXEL; PROTEIN KINASE C EPSILON; TEMOZOLOMIDE; VEMURAFENIB; VINBLASTINE; ATF2 PROTEIN, HUMAN; BETA INTERFERON; PRKCE PROTEIN, HUMAN;

5' UNTRANSLATED REGION; ARTICLE; CANCER INHIBITION; CELL AGING; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL STRESS; CELL VIABILITY; CELLULAR DISTRIBUTION; CUTANEOUS MELANOMA; CYTOSOL; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA CELL; METASTATIC MELANOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; S PHASE CELL CYCLE CHECKPOINT; SENESCENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; CELL NUCLEUS; DOWN REGULATION; DRUG RESISTANCE; GENETIC TRANSCRIPTION; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ACTIVATING TRANSCRIPTION FACTOR 2; CELL LINE, TUMOR; CELL NUCLEUS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERON-BETA; MELANOMA; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C-EPSILON; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 84947044632     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.22     Document Type: Article

References (35)

1. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014; 508: 118-122.
2. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-972.
3. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-977.
4. Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014; 4: 94-109.
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEnglJ Med 2010; 363: 711-723.
6. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
7. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020-1030.
8. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
10. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007; 25: 5426-5434.
11. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24.
12. Rubin KM. Management of primary cutaneous and metastatic melanoma. Semin Oncol Nurs 2013; 29: 195-205.
13. Schuchter LM. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin Oncol 2004; 22: 7-10.
14. Lau E, Kluger H, Varsano T, Lee K, Scheffler I, Rimm DL et al. PKCepsilon promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Cell 2012; 148: 543-555.
15. Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 2014; 20: 1138-1146.
16. Bhoumik A, Jones N, Ronai Z. Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci USA 2004; 101: 4222-4227.
17. Varsano T, Lau E, Feng Y, Garrido M, Milan L, Heynen-Genel S et al. Inhibition of melanoma growth by small molecules that promote the mitochondrial localization of ATF2. Clin Cancer Res 2013; 19: 2710-2722.
18. Mirzoeva OK, Petrini JH. DNA replication-dependent nuclear dynamics of the Mre11 complex. Mol Cancer Res 2003; 1: 207-218.
19. Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhovel S et al. Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol 2013; 133: 1601-1609.
20. Pencheva N, Buss CG, Posada J, Merghoub T, Tavazoie SF. Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell 2014; 156: 986-1001.
21. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol 2005; 23: 8057-8064.
22. Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R et al. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res 2010; 16: 2402-2408.
23. Gajewski TF, Fuertes MB, Woo SR. Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother 2012; 61: 1343-1347.
24. Jacobs AT, Ignarro LJ. Lipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW 264.7 macrophages. J Biol Chem 2001; 276: 47950-47957.
25. Malmgaard L, Salazar-Mather TP, Lewis CA, Biron CA. Promotion of alpha/beta interferon induction during in vivo viral infection through alpha/beta interferon receptor/STAT1 system-dependent and -independent pathways. J Virol 2002; 76: 4520-4525.
26. Wang J, Basagoudanavar SH, Wang X, Hopewell E, Albrecht R, Garcia-Sastre A et al. NF-kappa B RelA subunit is crucial for early IFN-beta expression and resistance to RNA virus replication. J Immunol 2010; 185: 1720-1729.
27. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18: 158-166.
28. Rao RD, Holtan SG, Ingle JN, Croghan GA, Kottschade LA, Creagan ET et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 2006; 106: 375-382.
29. Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A et al. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol 2009; 20: vi22-vi29.
30. Bhoumik A, Takahashi S, Breitweiser W, Shiloh Y, Jones N, Ronai Z. ATM-dependent phosphorylation of ATF2 is required for the DNA damage response. Mol Cell 2005; 18: 577-587.
31. Eiro N, Bermudez-Fernandez S, Fernandez-Garcia B, Atienza S, Beridze N, Escaf S et al. Analysis of the expression of interleukins, interferon beta, and nuclear factor-kappa B in prostate cancer and their relationship with biochemical recurrence. J Immunother 2014; 37: 366-373.
32. Snijders AM, Langley S, Mao JH, Bhatnagar S, Bjornstad KA, Rosen CJ et al. An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival. Oncotarget 2014; 5: 4011-4025.
33. Ryu H, Oh JE, Rhee KJ, Baik SK, Kim J, Kang SJ et al. Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-beta and suppress the growth of MCF-7 human breast cancer cells. Cancer Lett 2014; 352: 220-227.
34. Maeda S, Wada H, Naito Y, Nagano H, Simmons S, Kagawa Y et al. Interferon-alpha acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line. J Biol Chem 2014; 289: 23786-23795.
35. Yue C, Xu J, Tan Estioko MD, Kotredes KP, Lopez-Otalora Y, Hilliard BA et al. Host STAT2/type I interferon axis controls tumor growth. Int J Cancer 2014; 136: 117-126.